27467556|t|Prevalence and Hospital Management of Amphotericin B Deoxycholate -Related Toxicities during Treatment of HIV - Associated Cryptococcal Meningitis in South Africa
27467556|a|We aimed to establish the prevalence of amphotericin B deoxycholate (AmBd)-related toxicities among South African patients with cryptococcosis and determine adherence to international recommendations to prevent, monitor and manage AmBd -related toxicities. Clinical data were collected from cases of laboratory-confirmed cryptococcosis at 25 hospitals, October 2012 -February 2013. Anemia was defined as hemoglobin (Hb) concentration <10 g/dl, hypokalemia as serum potassium (K) <3.4 mEq/L and nephrotoxicity as an increase in serum creatinine (Cr) to >1.1 times the upper limit of normal. To determine adherence to toxicity prevention recommendations, we documented whether baseline Hb, K and Cr tests were performed, whether pre-emptive hydration and IV potassium chloride (KCl) was administered prior to 80% and 60% of AmBd doses and whether daily oral KCl supplementation was given â‰¥60% of the time. To determine adherence to monitoring recommendations, we ascertained whether a daily fluid chart was completed, Hb was monitored weekly and K or Cr were monitored bi-weekly. Of 846 patients, clinical data were available for 76% (642/846), 82% (524/642) of whom received AmBd. Sixty-four per cent (n = 333) had documented baseline laboratory tests, 40% (n = 211) were given pre-emptive hydration and 14% (n = 72) and 19% (n = 101) received intravenous and oral KCl. While on AmBd, 88% (n = 452) had fluid monitoring; 27% (n = 142), 45% (n = 235) and 44% (n = 232) had Hb, K and Cr levels monitored. Toxicities developed frequently during treatment: anemia, 16% (86/524); hypokalemia, 43% (226/524) and nephrotoxicity, 32% (169/524). AmBd -related toxicities occurred frequently but were potentially preventable with adequate monitoring, supplemental fluid and electrolyte therapies.
27467556	15	34	Hospital Management	T058	UMLS:C0019948
27467556	38	65	Amphotericin B Deoxycholate	T103	UMLS:C0051761
27467556	75	85	Toxicities	T037	UMLS:C0013221
27467556	93	102	Treatment	T058	UMLS:C0087111
27467556	106	109	HIV	T038	UMLS:C0019693
27467556	112	122	Associated	T038	UMLS:C0243083
27467556	123	146	Cryptococcal Meningitis	T038	UMLS:C0085436
27467556	150	162	South Africa	T082	UMLS:C0037712
27467556	203	230	amphotericin B deoxycholate	T103	UMLS:C0051761
27467556	232	236	AmBd	T103	UMLS:C0051761
27467556	246	256	toxicities	T037	UMLS:C0013221
27467556	263	276	South African	T098	UMLS:C0238605
27467556	291	305	cryptococcosis	T038	UMLS:C0010414
27467556	375	382	monitor	T058	UMLS:C0150369
27467556	394	398	AmBd	T103	UMLS:C0051761
27467556	408	418	toxicities	T037	UMLS:C0013221
27467556	420	433	Clinical data	T170	UMLS:C1516606
27467556	463	498	laboratory-confirmed cryptococcosis	T038	UMLS:C0010414
27467556	505	514	hospitals	T092	UMLS:C0019994
27467556	545	551	Anemia	T038	UMLS:C0002871
27467556	567	577	hemoglobin	T103	UMLS:C0019046
27467556	579	581	Hb	T103	UMLS:C0019046
27467556	607	618	hypokalemia	T033	UMLS:C0020621
27467556	622	637	serum potassium	T058	UMLS:C0302353
27467556	639	640	K	T058	UMLS:C0302353
27467556	657	671	nephrotoxicity	T037	UMLS:C0599918
27467556	690	706	serum creatinine	T058	UMLS:C0201976
27467556	708	710	Cr	T058	UMLS:C0201976
27467556	766	775	adherence	T033	UMLS:C2364172
27467556	779	787	toxicity	T037	UMLS:C0013221
27467556	847	849	Hb	T058	UMLS:C0518015
27467556	857	865	Cr tests	T058	UMLS:C0201976
27467556	890	911	pre-emptive hydration	T033	UMLS:C1321013
27467556	919	937	potassium chloride	T103	UMLS:C0032825
27467556	939	942	KCl	T103	UMLS:C0032825
27467556	985	989	AmBd	T103	UMLS:C0051761
27467556	1023	1038	supplementation	T103	UMLS:C0561938
27467556	1093	1119	monitoring recommendations	T058	UMLS:C3494704
27467556	1152	1163	fluid chart	T058	UMLS:C0016286
27467556	1179	1181	Hb	T103	UMLS:C0019046
27467556	1186	1195	monitored	T058	UMLS:C1283169
27467556	1207	1208	K	T058	UMLS:C0302353
27467556	1212	1214	Cr	T058	UMLS:C0201976
27467556	1220	1229	monitored	T058	UMLS:C1283169
27467556	1258	1271	clinical data	T170	UMLS:C1516606
27467556	1337	1341	AmBd	T103	UMLS:C0051761
27467556	1397	1413	laboratory tests	T058	UMLS:C0022885
27467556	1440	1461	pre-emptive hydration	T033	UMLS:C1321013
27467556	1506	1517	intravenous	T082	UMLS:C0013125
27467556	1541	1545	AmBd	T103	UMLS:C0051761
27467556	1565	1581	fluid monitoring	T058	UMLS:C0150237
27467556	1634	1636	Hb	T033	UMLS:C0019029
27467556	1638	1639	K	T033	UMLS:C0543465
27467556	1644	1653	Cr levels	T033	UMLS:C0600061
27467556	1654	1663	monitored	T058	UMLS:C1283169
27467556	1665	1675	Toxicities	T037	UMLS:C0013221
27467556	1704	1713	treatment	T058	UMLS:C0087111
27467556	1715	1721	anemia	T038	UMLS:C0002871
27467556	1737	1748	hypokalemia	T033	UMLS:C0020621
27467556	1768	1782	nephrotoxicity	T037	UMLS:C0599918
27467556	1799	1803	AmBd	T103	UMLS:C0051761
27467556	1813	1823	toxicities	T037	UMLS:C0013221
27467556	1891	1901	monitoring	T058	UMLS:C1283169